Patel Chintu - 03 Mar 2026 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Reporting relationship: Co-CEO, Director
Issuer ticker: AMRX
Reported as of: 03 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2026, 16:52:25 UTC
Prior SEC filing: 27 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Denis Butkovic, Attorney-in-Fact

Key filing fact

Patel Chintu filed Form 4 for Amneal Pharmaceuticals, Inc. (AMRX) on 05 Mar 2026.

Key facts

This page summarizes Patel Chintu's Form 4 filing for Amneal Pharmaceuticals, Inc. (AMRX).
9 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 05 Mar 2026, 16:52.

Change

Previous filing in this sequence was filed on 27 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001737428 Primary reporting owner

Patel Chintu

Relationship: Co-CEO, Director
Address: C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMRX transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +59,931
Change %: +6.9%
Price
Shares after: 923,964
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F1, F2

AMRX transaction

Class A Common Stock

Tax liability

Transaction value
Shares: -17,112
Change %: -1.9%
Price: $13.31^*
Shares after: 906,852
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F3

AMRX transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +733,944
Change %: +81%
Price
Shares after: 1,640,796
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F4

AMRX transaction

Class A Common Stock

Tax liability

Transaction value
Shares: -315,885
Change %: -19%
Price: $13.31^*
Shares after: 1,324,911
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F5

AMRX transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +92,593
Change %: +7%
Price
Shares after: 1,417,504
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1, F2

AMRX transaction

Class A Common Stock

Tax liability

Transaction value
Shares: -28,983
Change %: -2%
Price: $13.30^*
Shares after: 1,388,521
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F3

AMRX holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 24,753,252
Date: 03 Mar 2026
Ownership: By Family Trusts

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMRX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -59,931
Change %: -25%
Price: $0.000000^*
Shares after: 179,795
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 59,931
Exercise price
Footnotes: F2, F6

AMRX transaction Derivative

Performance-Based Restricted Stock Units

Options Exercise

Transaction value
Shares: -733,944
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 733,944
Exercise price
Footnotes: F4

AMRX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -92,593
Change %: -33%
Price: $0.000000^*
Shares after: 185,185
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 92,593
Exercise price
Footnotes: F2, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Footnote F3

Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

Footnote F4

Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

Footnote F5

Represents shares of common stock withheld to satisfy tax withholding obligations relating to vesting of performance-based restricted stock units.

Footnote F6

On March 3, 2025, the Reporting Person was granted 239,726 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Footnote F7

On March 4, 2024, the reporting person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.